Escolar Documentos
Profissional Documentos
Cultura Documentos
Author
Nancy J Roizen, MD
Section Editors
Jan E Drutz, MD
Helen V Firth, DM, FRCP, DCH
Deputy Editor
Mary M Torchia, MD
Head and neck — Characteristic dysmorphic features of DS affecting the head and neck
include:
Brachycephaly
Upslanting palpebral fissures
Epicanthic folds (picture 1)
Brushfield spots
Flat nasal bridge
Folded or dysplastic ears
Small ears
Open mouth
Protruding tongue (picture 1)
Furrowed tongue
Narrow palate
Abnormal teeth
Short neck
Excessive skin at nape of the neck
Neonatal features — Among the characteristic dysmorphic features, ten are common in
newborns with DS and are usually recognized soon after birth. In a series of 48 affected
newborns, all had four or more features and 89 percent had six or more [1,3].
Developmental impairment becomes apparent in the first year of life. In general, the
average age of sitting (11 months), creeping (17 months), and walking (26 months) is twice
the typical age [5]. Although the sequence of language development is the same, the rate is
slower, with the average age for the first word at 18 months [6]. The child with DS
continues to learn new skills. However, IQ declines through the first 10 years of age,
reaching a plateau in adolescence that continues into adulthood [2,7,8].
The profile of cognitive impairment in DS appears to differ from other forms of intellectual
disability. The most common profile, in which language comprehension is equal to mental
age and language production is more delayed, occurs in 64 percent of affected children [9].
In 34 percent, language comprehension, mental age, and language production are equal.
Impairment in expressive language was noted in another study of children with DS, who
had fewer different and total words and decreased mean length of utterance compared to
controls matched for nonverbal mental age [10]. Vocabulary skills accelerated more rapidly
than syntax (average sentence length and structure) and surpassed mental age in
adolescence. Similar findings of increasing differences in comprehension with age were
noted in another report, in which children with DS developed relatively stronger skills in
vocabulary compared to syntax [11]. Other selective deficits have been described, such as
greater difficulty understanding sequences or grammatical rules [2,12].
Some asymptomatic adolescents and adults without structural heart disease develop valve
abnormalities [14,15]. In a series of 35 patients with DS at an average age of 20 years,
mitral valve prolapse occurred in 16 (46 percent) and aortic regurgitation in two [14]. In
another report of 30 adults, mitral valve regurgitation occurred in 17 percent [15].
Hirschsprung disease is more common in DS than in the general population, although the
risk is less than 1 percent [4]. Among children with Hirschsprung disease, approximately 2
percent have trisomy 21, (with a range of 2 to 15 percent) [17-21].
A strong association appears to exist between DS and celiac disease. The prevalence of
biopsy-proven celiac disease has been reported to be between 5 and 16 percent,
representing a 5- to 16-fold increase compared to the general population [22-26].
GROWTH — Birth weight, length, and head circumference are less in DS compared to
typical infants. Newborns with DS weigh approximately 0.18 to 0.37 kg less than their
siblings [27]. Mean length at birth is approximately 0.5 standard deviation less than control
newborns [28].
In a study of 105 children with Down syndrome, length, weight, and head circumference
were below those of normal healthy children at birth; remained lower until puberty, with
the growth spurt being earlier (age 11 in boys and 9.5 in girls); and were blunted compared
with controls [29].
Obesity — The prevalence of obesity (defined as a body mass index >27.8 kg/m2 in adult
males and >27.3 kg/m2 in adult females) is greater in DS than in the general population (45
versus 33 percent, 56 versus 36 percent, for males and females, respectively) [31]. This is
thought to result from the reduced resting metabolic rate in children and adults with DS
[43,44]. In general, weight is less than expected for length in infants with DS, and then
increases disproportionally so that the majority of children are obese by age three to four
years [8].
Cataracts occur in 5 percent of newborns. Starting in the second decade of life, many
individuals develop corneal opacities. Children occasionally develop glaucoma
The frequency of ocular disorders increases with age. In one report, eye abnormalities
occurred in 38 percent of infants two to 12 months of age and 80 percent of children age
five to 12 years [45]. These abnormalities may be more prevalent in adults. In one report, of
30 institutionalized adults with Down syndrome, only one had nearly normal ocular status
[50]. Nine had keratoconus, an abnormal shape or thinning of the cornea that impairs visual
acuity.
Children with DS often have macrocytosis [55,57]. In one study, mean corpuscular volume
(MCV) was greater in DS children age two to six years compared to controls (86.9 versus
80.6 fL), and MCV >95th percentile for age was more likely to occur (66 versus 11
percent) [57]. Hematocrits were higher in the DS patients (39.1 versus 36.9 percent),
although all were normal for age.
White blood cell counts are decreased in DS [55,57]. In the study cited above, white blood
cell counts <5th percentile for age occurred more often in DS than controls (33 versus 6
percent) [57]. The macrocytosis and leukopenia were not explained by folate deficiency
because serum and red blood cell folate concentrations were similar between the patients
and controls. Thrombocytosis is common in infancy and thrombocytopenia is rare [55].
Of interest, a mouse model of trisomy 21 displays many of the hematologic features of DS,
including macrocytosis and a myeloproliferative disorder characterized by profound
thrombocytosis, megakaryocytic hyperplasia with dysplastic morphology, and
myelofibrosis [58,59]. The candidate gene(s) has not been identified.
Transient leukemia is characterized by the presence of primitive cells (ie, blasts) in the
peripheral blood [63]. The number of blasts varies from few to more than 200,000/microL.
Hemoglobin and neutrophil counts are typically normal. Platelet counts are usually normal,
although thrombocytopenia or thrombocytosis can occur. Giant platelets and fragments of
megakaryocytes may be seen. In the majority of cases, the number of blasts gradually
decreases. Blasts and platelet abnormalities spontaneously disappear before three months of
age. In DS infants with transient leukemia, in contrast to acute megakaryoblastic leukemia,
the percentage of blasts is lower in bone marrow than in peripheral blood and the bone
marrow cytogenetics reveal no clonal abnormalities other than trisomy 21 [66].
Most affected patients are asymptomatic. Vesiculopustular skin eruptions are common and
resolve as the hematologic disorder regresses [67,68]. The lesions contain cells similar to
the circulating blasts.
Hepatic fibrosis presents as obstructive jaundice that is progressive and results in death in
approximately one-half of the cases [69,71]. The mechanism of fibrosis may be related to
increased expression of platelet-derived growth factor and transforming growth factor beta
1 in the blast cells [72].
AML-M7 occurs in approximately one in 50 to 200 children with Down syndrome. The
incidence is approximately 500 times greater in children with than without DS. Studies
under way by the Children's Oncology Group and others will provide more information on
the natural history of transient leukemia, the proportion of patients who develop AML-M7
or acute lymphoblastic leukemia, their characteristics, and responses to treatment
[65,75,76].
AML-M7 develops during the first four years of life. It is most commonly seen by two
years of age and is invariably associated with mutations in GATA1 [54]. In contrast,
myeloid leukemias in people with DS aged four years or older are usually negative for
GATA-1 mutations, and their prognosis does not differ from AML in patients without DS.
Many affected patients (20 to 69 percent) present with myelodysplastic syndrome,
consisting of progressive thrombocytopenia followed by anemia [53]. Some develop
hepatomegaly and liver failure due to fibrosis [73] Neutropenia and infection rarely are
seen [73]. Treatment issues are complex, as children with Down syndrome and either ALL
or AML are subject to high initial rates of treatment-related mortality [77].
AML-M7 may result from a mutation in the gene on the X chromosome encoding the
transcription factor GATA-1 that is required for normal differentiation of megakaryocytes
[63,78-80]. In one report, mutations in GATA-1 were identified in blasts of all seven
infants with DS and transient leukemia [81]. In another study, GATA-1 mutations were
found in blasts of nine of 12 patients with DS and transient leukemia and all three with
AML-M7 [82]. In one patient studied serially, the same mutation was identified in blasts
during transient leukemia diagnosed before one week of age and in subsequent AML-M7 at
one year, but not after remission at three years.
There is evidence that these GATA-1 mutations are acquired in utero and that finding such
mutations at birth might serve as a biomarker for an increased risk of transient leukemia
and subsequent AMKL [83,84]. In one study, three of four children with DS and AMKL
had the same GATA-1 mutation in a neonatal blood spot (Guthrie card) that was found at
the time of clinical diagnosis of AMKL 12 to 26 months later [85].
Gene expression profiling may help in distinguishing transient leukemia from AMKL [86],
as well as distinguishing the AMKL seen in children with DS from AMKL seen in those
without DS [87].
In a report comparing ALL in DS and non-DS children, the following findings were noted
at presentation [53,88]:
Children with DS who develop ALL often respond to chemotherapy as well as do children
without DS. The treatment and outcome for children with DS and ALL are discussed
separately.
Thyroid disease — Thyroid disorders are common in DS. The prevalence varies, depending
in part upon the population studied and the age of testing. In reports of adults with DS, the
prevalence of hypothyroidism ranged from three to 54 percent [99]. Hyperthyroidism is
also relatively common, occurring in 2.5 percent of institutionalized adults [100].
Thyroid disease is also common in children with DS, as indicated in the following reports.
REPRODUCTION — Women with DS are fertile and may become pregnant. In one
series, 30 pregnancies in 26 women resulted in 10 offspring with DS, 18 (including one set
of twins) without DS, and three spontaneous abortions [106]. Appropriate counseling
should be provided for management of menstruation and contraception [4].
Nearly all males with DS are infertile. The mechanism is impairment of spermatogenesis
[107]. However, cases have been reported of offspring from fathers with DS [108,109].
Patients with symptomatic spinal cord compression may have neck pain, torticollis, gait
abnormalities, loss of bowel or bladder control, or signs of quadriparesis or quadriplegia,
and require immediate stabilization. Asymptomatic individuals appear to remain
asymptomatic whether or not physical activity is restricted [112,113]. In one study, DS
children with AAI were randomly assigned to participate or not in athletic activities
considered to be risky and evaluated after one year. The groups were similar in motor
function, frequency of neurologic signs, and changes in atlantoaxial distance, and were also
similar to children with DS and without AAI [112].
SKIN DISORDERS — The majority of DS children have associated skin disorders, which
are considered benign. In one series, 62 of 71 children (87 percent) had skin abnormalities
in the following proportions [123]:
REFERENCES
The Committee on Genetics of the American Academy of Pediatrics (AAP) has provided
recommendations to assist clinicians in the care of children with DS [1]. These
recommendations are available at
pediatrics.aappublications.org/cgi/content/full/107/2/442/T1. The recommendations for
medical evaluation are summarized in table 1 (table 1). Management requires an organized
approach to initial and ongoing evaluation and monitoring for associated abnormalities and
prevention of common disorders [2]. The management and life expectancy of children with
Down syndrome will be presented here.
CARDIAC DISEASE — All newborns with DS should be evaluated for congenital heart
disease in consultation with a pediatric cardiologist. An echocardiogram is recommended to
detect abnormalities that may not be symptomatic or apparent on physical examination.
Continued clinical cardiac evaluation is needed because of the high risk of mitral valve
prolapse and aortic regurgitation in adolescents and young adults [2].
HEARING — Newborns should have a newborn hearing screen and, if this is not passed, a
full hearing evaluation by brainstem auditory evoked response and otoacoustic emission.
Hearing should be evaluated regularly throughout childhood [1]. Children should be
evaluated and treated for otitis media, which occurs commonly.
CELIAC DISEASE — Screening for celiac disease should begin at two years of age.
Repeat screening should be considered if signs or symptoms develop [11].
Routine brushing should be encouraged. Dental visits are recommended every six months.
Orthodontic problems, which occur in the majority of DS patients, should be evaluated.
These should be treated if possible. However, the cooperation necessary for many
orthodontic procedures may make them impractical in this population.
Thus, instead of screening radiographs, the AAP Committee on Sports Medicine and
Fitness recommends careful neurologic evaluation for signs and symptoms consistent with
spinal cord injury (eg, loss of motor skills, loss of bowel or bladder control, neck pain, neck
stiffness) as the most important clinical predictor of symptomatic atlantoaxial instability
and dislocation [15]. The evaluating clinician should take a careful history and perform a
thorough physical examination, looking for evidence of neurologic involvement. This
clinical screening process should be done at least annually [15]. Symptomatic children
should have an MRI to clarify the extent of spinal cord compression, and appropriate
surgical consultation should be obtained to evaluate the need for definitive treatment.
Despite these recommendations, the Special Olympics requires screening neck radiographs
in children with DS before participation. Children who are found to have AAI on these
radiographs but who lack neurologic symptoms should be followed closely with repeat
neurologic examinations (at least annually) [15].
SLEEP APNEA — Children with DS have an increased risk of obstructive sleep apnea
because of soft tissue and skeletal alterations that lead to upper airway obstruction.
Symptoms related to sleep apnea (snoring, restless sleep, and sleep position) should be
discussed at health supervision visits beginning at age one year and continuing throughout
childhood [1]. Polysomnography may be indicated in symptomatic children, whether or not
they are obese [17].
In the same report, malignancies other than leukemia were much less frequent in those with
than without DS (standardized mortality odds ratio 0.07) [18]. Possible mechanisms
suggested for the low rate of cancer include tumor suppressor genes on chromosome 21, a
slower rate of replication or higher rate of apoptosis in DS cells, or less exposure to
environmental risks.
Survival in DS is affected by race and sex [18,20]. In the death certificate study noted
above, the median age at death was lower among blacks than whites [18]. In contrast to the
greater longevity of females in most populations, males with DS appear to have a survival
advantage [21,22]. In a series from Western Australia, life expectancy was 58.6 years for
the population, and 3.3 years longer for males than females [21].
Supplementation with antioxidant nutrients has been proposed as potential therapy for DS.
Treatments studied include supplementation with zinc, selenium, megavitamins and
minerals, vitamin A, vitamin B6, 5-hydroxytryptamine, coenzyme Q10, and targeted
nutritional intervention [25,28,29]. These studies have methodologic flaws and provide no
convincing evidence that nutritional supplementation improves outcomes in DS. One
randomized controlled trial evaluated psychomotor and language development in 156
infants treated for 18 months with daily oral supplementation with one of four programs:
antioxidants (selenium, zinc, vitamin A, vitamin E, vitamin C), folinic acid, antioxidants
and folinic acid combined, or placebo. This trial found no significant differences between
the groups [29].
A brochure entitled, "Your baby and Down syndrome: Answers to questions you might
have," available in English and Spanish, can be downloaded from the National Down
Syndrome Society Web site.
REFERENCES
Thyroid Newborn screen (in accordance with state law), 6 months, 12 months,
screening and annually thereafter
Complete blood
At neonatal visit and annually between 13 and 21 years
count